Objective: Osteoclastogenic activation of macrophages (OCG) occurs in human abdominal aortic aneurysms (AAAs) and in calcium chloride-induced degenerative AAAs in mice, which have increased matrix metalloproteinase activity. As the activity of OCG in dissecting aneurysms is not clear, we tested the hypothesis that OCG contributes to angiotensin II (Ang II)-induced dissecting aneurysm (Ang II-induced AAA) in apolipoprotein E knockout mice.
Conclusions: OCG with increased RANKL expression was present in Ang II-induced AAA, and neutralization of RANKL suppressed AAA formation. As neutralization of RANKL has been used clinically to treat osteoporosis and other osteoclast-related diseases, additional study of the effectiveness of RANKL neutralization in AAA is warranted. (J Vasc Surg 2018;68:48S-59S.)
Clinical Relevance: We previously demonstrated that osteoclastogenic differentiation of macrophages (OCG) plays an important role in the development of human abdominal aortic aneurysms and murine calcium chloride-induced degenerative abdominal aortic aneurysms. In angiotensin II-induced dissecting aneurysm, we demonstrated the presence of OCG and its induction by receptor activator of nuclear factor kB ligand, which is a stimulator of osteoclast formation in apolipoprotein E knockout mice. Neutralization of receptor activator of nuclear factor kB ligand significantly suppressed the development of angiotensin II-induced dissecting aneurysm, suggesting that targeting of OCG could be an effective therapeutic approach to dissecting aneurysm.
Abdominal aortic aneurysm (AAA) is among the 20 leading causes of death in the United States. Currently, open surgical repair and endovascular placement of a stent graft are the only proven treatments for AAA. The significant morbidity and mortality associated with treatment emphasize the need for alternative therapeutic strategies. Studies have demonstrated the involvement of balanced mineralization in diseased arteries through the tight control of calcification by osteoblast-like and osteoclast-like cells (OCLs). 3, 4 OCLs are similar to osteoclasts but occur in tissues other than bone, differentiate from monocyte-macrophages, and, histologically, are multinucleate cells positive for tartrate-resistant acid phosphatase (TRAP) staining. We previously demonstrated the role of the receptor activator of nuclear factor kB ligand (RANKL) in stimulating the differentiation of macrophages into TRAP-positive OCLs in vitro. 5 RANKL is generally expressed in the bone and is essential for formation of mature osteoclasts, which express matrix metalloproteinase (MMP) 9 that facilitates migration of osteoclasts to resorption sites through the extracellular matrix. 6, 7 We previously demonstrated that osteoclastogenic differentiation of macrophages (OCG) plays an important role in the development of aneurysms through stimulation of tumor necrosis factor a plus calcium phosphate, 5 but the involvement of OCG in dissecting AAA is still unclear. Dissecting aneurysm is distinguished from degenerative aneurysm as occurring after the aortic dissection that induces tearing of the medial layer of the aorta, resulting in the pooling of blood within the vessel layers and subsequent hematoma formation. Angiotensin II (Ang II)-infused apolipoprotein E-deficient (apoE À/À ) mice are accepted mouse models of dissecting AAA. Medial accumulation of macrophages and dissection are early events in Ang II-induced AAA. 8 Gavrila et al 9 suggested that this model more closely resembles aortic dissection than common aneurysm formation in humans.
Here, we tested the hypothesis that OCG contributes to Ang II-induced dissecting aneurysm in apoE À/À mice.
METHODS
Materials. RANKL-neutralizing antibody was purchased from Oriental Yeast (Tokyo, Japan). TG101348, a selective inhibitor of Janus kinase 2 (JAK2) tyrosine kinase, was purchased from Santa Cruz Biotechnology (Dallas, Tex). Ang II and RANKL antibodies for immunohistochemical staining were purchased from Millipore (Billerica, Mass) and Cell Signaling Technology (Danvers, Mass). All chemicals used in this study were of the highest purity available.
Cell culture. Murine vascular smooth muscle cells (MOVAS cells) were purchased from American Type Culture Collection (Manassas, Va) and maintained in Dulbecco modified Eagle medium containing 10% fetal bovine serum (FBS) and 1% G418 (Cellgro Mediatech, Herndon, Va). The murine macrophage cell line RAW 264.7 (American Type Culture Collection) was maintained in high-glucose (4.5 g/L) Dulbecco modified Eagle medium supplemented with 10% FBS and 100 IU/mL penicillin/100 mg/mL streptomycin. MOVAS cells (passage number 5-10) were seeded in multiwell plates at a density of 1.0 Â 10 4 cells/cm 2 . At 100% confluence, the medium was supplemented with 0.1 to 10 mM of Ang II for 0 to 72 hours. Cells were incubated at 37 C in a humidified atmosphere of 95% air/5% carbon dioxide; the culture medium was changed every second or third day.
Animals and treatments. Retired male breeder apoE
À/À mice >6 months of age were obtained from the Jackson Laboratory (Bar Harbor, Me). All Ang II-treated mice received Ang II (1000 ng/min/kg) through continuous infusion by an osmotic pump (Alzet model 1004; Durect Corporation, Cupertino, Calif) implanted in the back of the mouse. Mice receiving either normal rat immunoglobulin G (control, n ¼ 6) or RANKL-neutralizing antibody (5 mg/kg; anti-RANKL group, n ¼ 5) were administered a subcutaneous injection, once, 7 days before Ang II infusion. After 28 days, the abdominal aorta was fixed by perfusion of 4% paraformaldehyde and harvested. The maximum diameter of the abdominal aorta was measured ex vivo with digital calipers to evaluate aneurysm formation. All animal procedures were conducted in accordance with experimental protocols that were approved by the Institutional Animal Care and Use Committee at the University of Wisconsin, Madison (protocol M02394).
Histologic, immunohistochemical, and immunofluorescence evaluation. Mouse aortas were embedded with OCT compound (Sakura Tissue Tek, Torrance, Calif), frozen, and sectioned at 6 mm. Enzymatic TRAP staining was performed with an acid phosphatase kit (Sigma Chemical, St. Louis, Mo). Immunohistochemical staining was done using a commercially available polymerbased detection system (ImmPACT and ImmPRESS; Vector Laboratories, Inc, Burlingame, Calif). To retrieve antigen activity, sections were microwaved in 0.1 mM citrate buffer (pH 6.0) for 5 minutes, and after blocking with 0.8% bovine serum albumin in tris-buffered saline (TBS) for 1 hour, the tissue sections were incubated with the mouse anti-RANKL primary antibody (ab45039; The expression level for each gene was normalized to Gapdh expression in the same sample.
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Methylthiazol tetrazolium (MTT) assay. MOVAS and RAW 264.7 cells were cultured to confluence in a 96-well plate as previously described in 100 mL of media per well. Cells were then treated with 1 mM Ang II, 1 mM
Ang II plus 100 ng/mL RANKL-neutralizing antibody, 100 ng/mL RANKL-neutralizing antibody alone, or left untreated for 48 hours. Five wells per treatment condition were prepared. After 2 days of incubation, cell proliferation was analyzed with the MTT cell proliferation assay kit (Cayman Chemical, Ann Arbor, Mich). Briefly, 10 mL of MTT reagent was added to each well, mixed gently, and allowed to incubate for 1 hour at 37 C in a carbon dioxide incubator. Next, 100 mL of dimethyl sulfoxide (Sigma) was added to each well, and the absorbance of each well was read at 570 nm using a FlexStation 3 microplate reader (Molecular Devices, Sunnyvale, Calif).
JC-1 assay. MOVAS and RAW 264.7 cells were cultured to confluence in a 96-well black culture plate as previously described in 100 mL of media per well. Cells were then treated with 1 mM Ang II, 1 mM Ang II plus 100 ng/mL RANKL-neutralizing antibody, 100 ng/mL RANKLneutralizing antibody alone, or left untreated for 48 hours. Five wells per treatment condition were prepared. After 2 days of incubation, apoptosis was analyzed with the JC-1 mitochondrial membrane potential assay kit according to the manufacturer's instructions (Cayman Chemical). Briefly, 10 mL of JC-1 staining solution was added to each well and allowed to incubate for 30 minutes at 37 C in a carbon dioxide incubator. The plate was then centrifuged for 5 minutes at 400 g, and the supernatant was removed. The wells were then washed twice with 200 mL of phosphate-buffered saline (PBS) and centrifuged for 5 minutes at 400 g, and the supernatant was removed. Last, 100 mL of PBS was added to each well, Ang II (1000 ng/ min/kg) was continuously infused by an osmotic pump implanted in the back of apoE À/À mice. After 28 days, the abdominal aortas were fixed by perfusion of 4% paraformaldehyde and harvested. The aortas were embedded in OCT, and frozen sections were cut for histologic, immunohistochemical, and immunofluorescence evaluation. A, Representative images of arteries stained with tartrate-resistant acid phosphatase (TRAP) and alizarin red in Ang II-infused mice. TRAP-positive cells (purple) were seen only in the medial layer of the Ang II-induced AAA. Alizarin red staining showed no positivity in either group. Scale bar ¼ 0. 
RESULTS
OCG in Ang II-induced AAA in ApoE À/À mice. We found aneurysms in all mice after 4 weeks of Ang II infusion and found purple-stained TRAP-positive multinuclear cells in the aneurysmal arteries of Ang II-induced mice (100%; N ¼ 10) but not in the control mice (N ¼ 5; Fig 1, A) . Next, we evaluated RANKL expression in tissues of Ang IIinduced AAA by immunohistochemistry. RANKL expression was significantly increased in Ang II-induced AAA tissue compared with control aortas (Fig 1, B) . Analysis of Western blots showed that RANKL expression was increased 1.7-fold in Ang II-induced AAA compared with the control aortas (Fig 1, C) . The results indicate that Ang II infusion induced RANKL expression in dissecting AAA. In addition, some costaining with the macrophage marker MOMA-2 and a marker of OCL, calcitonin receptor, was observed in Ang II-induced AAA tissue, further indicating the differentiation of macrophages in AAA (data not shown). We then investigated the location of RANKL expression in relation to smooth muscle actin and CD68 expression, which served as markers for vascular smooth muscle cells and macrophages, respectively. We found co-localization of RANKL-and smooth muscle actin-expressing cells in the medial layer of AAA tissue (Fig 1, D) . We also observed CD68 expression in the medial layer of aneurysmal tissue, confirming TRAP staining; however, CD68 does not appear to colocalize with RANKL (Fig 1, E) .
Ang II-induced RANKL expression in smooth muscle cells. To investigate the mechanism of macrophage differentiation into OCLs in Ang II-induced AAA, MOVAS cells (a murine aortic smooth muscle cell line) were treated with Ang II. Forskolin was used as a positive control for RANKL expression. As shown in Fig 2, A Expression of RANKL messenger RNA (mRNA) and protein was quantified by quantitative real-time polymerase expression starting at 12 hours after stimulation and continuing through 48 hours (0.9 6 0.1 at 12 hours vs 2.8 6 0.2 at 48 hours). Expression remained constant from 48 to 72 hours after stimulation. The same trend was observed in RANKL protein expression (Fig 2, D) . Densitometry analysis of Western blots indicated a 1.8-fold increase of RANKL expression at 48 hours after Ang II treatment.
Increased RANKL expression in smooth muscle cells through the JAK2/STAT5 pathway. We investigated JAK2/STAT5 activity as a possible signaling mechanism in MOVAS cells treated with Ang II. Phospho-JAK2 and STAT5 levels were increased by Ang II treatment (Fig 2, E) , and inhibition of JAK2 by TG101348 suppressed Ang II-induced RANKL expression (Fig 2, F) . The results suggest that the JAK2/STAT5 pathway is involved in the increase in RANKL expression in response to Ang II in MOVAS cells.
Treatment of MOVAS cells with Ang II and RANKLneutralizing antibody altered expression of osteogenic modulating proteins.
We demonstrated the importance of Ang II in stimulation of MOVAS cells to produce RANKL; therefore, we were interested in the effect of RANKL-neutralizing antibody on apoptosis, proliferation, and expression of proteins involved in the progression of vascular disease. To investigate effects of Ang II and RANKL-neutralizing antibody on apoptosis and proliferation of cells, we used the JC-1 mitochondrial membrane potential (Dj M ) and MTT assays, respectively. Ang II treatment of MOVAS cells alone or in combination with RANKL-neutralizing antibody did not have significant effects on apoptosis or proliferation in vitro (Fig 2, G and  H) . Treatment of MOVAS cells with Ang II plus RANKLneutralizing antibody resulted in significant stimulation of TIMP1 expression, and treatment with RANKLneutralizing antibody alone stimulated the expression of TIMP1 and BMP4 (Fig 2, I ). This suggests that in the absence of stimulation by RANKL, vascular smooth muscle cells may be involved in creation of an osteogenic vascular environment rather than the osteoclastogenic environment promoted by RANKL expression. In addition, we demonstrated the ability of Ang II to stimulate RANKL expression, confirming our previous observations ( Supplementary Fig, online only) .
RANKL stimulation of macrophages resulted in increased MMP9 expression. As MMP9 is secreted by macrophages and is involved in the development of aneurysms, 10 we assayed MMP9 expression in RAW 264.7 murine macrophage cells after RANKL stimulation. The RANKL treatment significantly increased both Mmp9 mRNA expression and protein secretion (Fig 3, A and B) .
The results suggest that Ang II-induced RANKL expression in vascular smooth muscle cells may stimulate MMP9 expression in macrophages.
RANKL neutralization-induced apoptosis is associated with decreased cell proliferation in RAW 264.7 macrophages. Given the importance of RANKL stimulation in osteoclastogenesis and MMP9 expression in macrophages, we examined the effect of treatment of RAW 264.7 cells with Ang II and RANKL-neutralizing antibody, alone or in combination. We observed that the combined treatment of Ang II and RANKL-neutralizing antibody significantly increased the ratio of apoptotic cells to healthy cells in vitro and resulted in decreased cell proliferation (Fig 3, C and D) . In addition, we examined the expression of various modulators of vascular disease by RAW 264.7 cells under the same culture conditions described previously. Ang II and RANKLneutralizing antibody, alone or in combination, did not significantly alter the expression of TIMP1, BMP4, TGF-b, MMP9, MMP2, or RANKL (Fig 3, E) . injection of RANKL-neutralizing antibody and six mice received normal rat immunoglobulin G as a control. However, during the first 2 weeks of Ang II infusion, two mice in the control group and one mouse in the anti-RANKL group died because of a ruptured aneurysm, confirmed by necropsy. 8 As shown in Fig 4, A and B, administration of RANKL-neutralizing antibody significantly suppressed aneurysm formation, indicated by the decrease in the maximum diameter of the aorta at the time of sacrifice (2.2 6 0.2 mm vs 1.5 6 0.4 mm; P < .05).
The suppression of OCG development through RANKL neutralization was evaluated by TRAP staining, which confirmed a significant decrease of TRAP-positive cells in mice that received RANKL-neutralizing antibody compared with controls (Fig 4, C) . The RANKLneutralizing antibody also significantly decreased Ang II-induced MMP9 expression in the aorta (Fig 4, D) . These results suggest that RANKL-neutralizing antibody suppressed Ang II-induced aneurysm through inhibition of OCG development.
DISCUSSION
We confirmed the presence of OCG in mice with Ang II-induced dissecting aneurysms as a result of Ang II-induced RANKL expression by vascular smooth cells. This study and our previous work showed the involvement of OCG in both degenerative and dissecting aneurysms, but the stimulation of OCG proceeded by distinct mechanisms. In degenerative aneurysms, OCG was induced through costimulation by calcium phosphate and tumor necrosis factor a. 5 In this study, RANKL induced OCG in dissecting aneurysms, and immunohistochemical analysis of Ang II-induced AAA confirmed increased RANKL expression compared with control aortas. Our hypothesis was that macrophages are stimulated to transition into OCLs in aneurysmal tissues. Therefore, we examined dissecting aneurysmal sections for TRAP-and CD68-positive cells and found the presence of both markers in the medial layer. Because CD68 is found on both recruited monocyte precursor cells and differentiated macrophage populations at the site of diseased vessels, it is possible that cells from both populations may mature into OCLs.
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Based on the results from co-localization staining, we focused on vascular smooth muscle cells as a source of RANKL, although we could not exclude other cell types as a potential source. We found that Ang II treatment of MOVAS cells induced significant increases in Rankl mRNA and protein expression, which corresponds to the previous findings of Osako et al.
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JAK2 and STAT5 were studied as possible mediators of Ang II-induced RANKL expression in vascular smooth muscle cells and were found to be significantly activated by Ang II. Ang II-induced JAK2/STAT5 activation in MOVAS cells was suppressed by a selective inhibitor of JAK2, TG101348, which inhibits polycythemia vera progenitor erythroid differentiation in mice, 13 suggesting that Ang II-induced RANKL expression in MOVAS cells proceeds through the JAK2/STAT5 pathway. When we investigated the effect of TG101348 inhibition of JAK2/ STAT5 in Ang II-induced AAA in mice, we found that the diameter of the aorta was not affected (data not shown). Therefore, further study with different dosages and methods of administration is needed. The involvement of RANKL in dissecting aneurysm formation was further indicated by the suppression of Ang II-induced AAA progression in mice after administration of RANKL-neutralizing antibody. Furthermore, we showed that RANKL-neutralizing antibody significantly reduced MMP9 expression in the aorta. This finding corroborates the importance of RANKL in stimulating MMP9 expression by macrophages in vitro and provides a link between RANKL stimulation and the production of an agent of aneurysm formation.
Suppression of aneurysm formation by RANKLneutralizing antibody prompted us to examine the role of Ang II and RANKL neutralization on vascular smooth muscle cells and macrophages in vitro. In vascular smooth muscle cells, RANKL neutralization increased expression of TIMP1 and BMP4 on RANKL neutralization. This increase is intuitive in light of the vital role RANKL plays in OCG aneurysm ontology that we exhibited and considering the role of TIMP1 in suppression of MMP function and the osteogenic function of BMP4. Furthermore, this result is consistent with previous findings that demonstrated decreased BMP4 expression in the murine Ang II model of AAA.
14 Our observation of increased apoptosis and decreased cell proliferation in macrophages cultured with RANKLneutralizing antibody is consistent with the role of RANKL-induced OCG we demonstrated in these studies. This finding also concurs with previous studies that revealed the antiapoptotic effect of RANKL on osteoclasts and the pathway by which this signal is propagated. 15 As such, RANKL plays a role in maintenance of macrophage populations that are well known to contribute to the inflammatory environment associated with aneurysmal disease. 16, 17 Thus, the activation and survival of macrophages through RANKL signaling appear vital to development of aneurysmal disease. As RANKL neutralization has been used clinically to treat osteoporosis and other osteoclast-related diseases, further study of the effectiveness of RANKL neutralization on AAA is warranted. The results of studies of the effects of bisphosphonates and osteoclast inhibitors on mouse aneurysms are inconsistent. Tsai et al 18 reported suppression of Ang II-induced AAA by daily administration of zoledronic acid. We have also studied the effect of zoledronic acid on Ang II-induced AAA. Only a single yearly intravenous injection is required for the treatment of osteoporosis in humans. Therefore, we evaluated the effect of a single injection of zoledronic acid in AngII-induced AAA but did not find a suppressive effect. 5 As bisphosphonates act by binding to calcium phosphate to exert its suppressive effect on osteoclastogenesis, 19 we speculated that the positive effect reported by Tsai et al was systemic rather than local because Ang II-induced AAA did not show arterial calcification, whereas degenerative aneurysms developed calcification.
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CONCLUSIONS
We demonstrated the presence of OCG associated with increased RANKL expression in Ang II-induced AAA. In vitro, Ang II induced RANKL expression by vascular smooth muscle cells through the JAK2/STAT5 signaling pathway, and RANKL-neutralizing antibody suppressed AAA formation. Although further studies are needed, these data suggest that RANKL-neutralizing antibody may be useful as a therapeutic agent to treat dissecting aneurysms.
We thank Jay Yang, MD, PhD, professor of the Department of Anesthesiology at the University of WisconsinMadison, for valuable comments and support. We are also grateful to our colleague Chitaru Kurihara, MD, for technical assistance. Precision medicine and molecular therapeutics offer significant potential in vascular patients because of the chronicity and heterogeneity of disease. Currently, there is no established, targeted molecular therapeutic intervention for abdominal aortic aneurysm (AAA) disease. The work on using metalloproteinase as a biomarker and targeting its activity as a therapeutic option continues on the basis of earlier work, in whole and in part, in murine models. Initial studies in humans have not come to fruition. 1 Other potential biologic interventions have also proved unsuccessful. Thus, a greater understanding of AAA pathobiology and the identification of one or more ligand or intracellular pathways that can interrupt the pathobiologic process of aneurysm formation remain important areas of study. The current study sheds more light on receptor activator of nuclear factor kB ligand (RANKL)-mediated osteoclastogenic differentiation of macrophages in a phenotypically unique model of AAA formation. Several studies have demonstrated that there is a balanced mineralization process within the wall of diseased arteries mediated by monocyte-macrophage-derived osteoblast-like and osteoclast-like cells. 2 Osteoclastogenic activation of macrophages has been described both in human AAAs and in experimental aneurysm formation. Mature osteoclasts express matrix metalloproteinase 9, which provides an iterative link back to the original hypotheses that matrix metalloproteinases have a role in AAA formation. The current study builds on this background and shows that osteoclast-like macrophages in AAA are associated with increased expression of RANKL. 2 Administration of a RANKLneutralizing antibody resulted in a significant decrease in the diameter of the experimental aneurysms. This would suggest that targeting RANKL may be a potential new therapeutic approach to inhibition of AAA growth. RANKL neutralization is currently used clinically to treat osteoporosis and other osteoclast-related diseases; thus, a medication and therapeutic profile in humans already exists. The importance of this paper is that it identifies a unique target within macrophages that reside within the wall of an AAA and this target has a known therapeutic antagonist in clinical practice. However, given the uniqueness of the model with a phenotype of a dissecting aortic aneurysm, validation in the other murine and nonmurine models of AAA will be necessary. Once validated, there will be a need to define the timing for RANKL intervention, to ensure precision in homing and targeting to an aneurysmal aortic wall, to estimate the duration of therapy (acute, pulsed, or chronic), and to ensure that there are no unintended cellular consequences in other arteries and organs. Irrespective of these issues, the current study reveals a novel and new pathway to interrupt AAA formation that has prospects to move to a clinical study and marks an advance in the understanding of the role of macrophages in AAA pathobiology.
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